Skip to main content

Sexually Transmitted Diseases

1
Pipeline Programs
9
Companies
11
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 13 programs with unclassified modality

Competitive Landscape

8 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
NgG low dose investigational vaccinePhase 1/2Vaccine
Human BioSciences
Human BioSciencesWV - Martinsburg
4 programs
Health-E You appN/A1 trial
P3N/A1 trial
Patient preferencesN/A1 trial
Risk Avoidance InterventionN/A1 trial
Active Trials
NCT06525064Not Yet Recruiting2,752Est. Dec 2027
NCT03320512Completed246Est. Sep 2021
NCT01862133Completed136Est. Mar 2014
+1 more trials
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
Pre Exposure ProphylaxisN/A
Pre Exposure ProphylaxisN/A
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
Risk ReductionN/A1 trial
uTECH + YMHPN/A1 trial
Active Trials
NCT01829282Unknown400Est. Jun 2017
NCT04710901Completed388Est. May 2024
Essential Pharmaceuticals
2 programs
Synthetic Nitrile CondomN/A1 trial
Synthetic Nitrile CondomsN/A1 trial
Active Trials
NCT06079060Completed305Est. Oct 2024
NCT05912283Completed600Est. Jan 2024
Kite Pharma
Kite PharmaCA - El Segundo
1 program
Pre Exposure ProphylaxisN/A1 trial
Active Trials
NCT02852226Completed30Est. Aug 2017
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
SexHealthN/A1 trial
Active Trials
NCT03341975CompletedEst. May 2020
Evofem Biosciences
Evofem BiosciencesCA - San Diego
1 program
EVO100PHASE_31 trial
Active Trials
NCT04553068Completed1,892Est. Jul 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Evofem BiosciencesEVO100
Human BioSciencesHealth-E You app
Essential PharmaceuticalsSynthetic Nitrile Condom
Essential PharmaceuticalsSynthetic Nitrile Condoms
Angeles TherapeuticsuTECH + YMHP
Human BioSciencesP3
City TherapeuticsSexHealth
Kite PharmaPre Exposure Prophylaxis
Human BioSciencesPatient preferences
Angeles TherapeuticsRisk Reduction
Human BioSciencesRisk Avoidance Intervention

Clinical Trials (11)

Total enrollment: 8,491 patients across 11 trials

NCT04553068Evofem BiosciencesEVO100

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

Start: Oct 2020Est. completion: Jul 20221,892 patients
Phase 3Completed
NCT06525064Human BioSciencesHealth-E You app

Health-E You Efficacy Trial for Male Adolescents

Start: Jun 2026Est. completion: Dec 20272,752 patients
N/ANot Yet Recruiting
NCT06079060Essential PharmaceuticalsSynthetic Nitrile Condom

Evaluation of Synthetic Nitrile Male Condom Compared to Standard Latex Male Condom

Start: Oct 2023Est. completion: Oct 2024305 patients
N/ACompleted
NCT05912283Essential PharmaceuticalsSynthetic Nitrile Condoms

Evaluation of 2 Synthetic Nitrile Male Condoms Compared to a Standard Latex Male Condom

Start: Jun 2023Est. completion: Jan 2024600 patients
N/ACompleted
NCT04710901Angeles TherapeuticsuTECH + YMHP

UTECH: Machine Learning for HIV Prevention Among Substance Using GBMSM

Start: Nov 2020Est. completion: May 2024388 patients
N/ACompleted
NCT03320512Human BioSciencesP3

P3 (Prepared, Protected, emPowered)

Start: May 2019Est. completion: Sep 2021246 patients
N/ACompleted
NCT03341975City TherapeuticsSexHealth

Enhanced SexHealth Intervention to Improve Adolescent Outcomes

Start: Dec 2017Est. completion: May 2020
N/ACompleted
NCT02852226Kite PharmaPre Exposure Prophylaxis

CRUSH-PrEP for Women Project

Start: May 2016Est. completion: Aug 201730 patients
N/ACompleted
NCT01862133Human BioSciencesPatient preferences

Aspiring to Awesome- Patient Preference Privacy Selections in EMR

Start: Aug 2013Est. completion: Mar 2014136 patients
N/ACompleted
NCT01829282Angeles TherapeuticsRisk Reduction

Eban II: Intervention for HIV Sero-Discordant Couples

Start: Jul 2012Est. completion: Jun 2017400 patients
N/AUnknown
NCT00167505Human BioSciencesRisk Avoidance Intervention

All About Youth: Evaluation of Sexual Risk Avoidance and Risk Reduction Programs for Middle School Students

Start: Sep 2006Est. completion: Jul 20101,742 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.